Загрузка...
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
PURPOSE: To assess the tumor response to the smoothened (SMO) inhibitor, sonidegib (LDE225), in patients with an advanced basal cell carcinoma (BCC) resistant to treatment with vismodegib (GDC0449). EXPERIMENTAL DESIGN: Nine patients with an advanced BCC that was previously resistant to treatment wi...
Сохранить в:
| Опубликовано в: : | Clin Cancer Res |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4794361/ https://ncbi.nlm.nih.gov/pubmed/26546616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1588 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|